Company intelligence / Profile preview

PriZm Therapeutics

Ownership: Private
Development stage: Other

Overview

PriZm Therapeutics is advancing SRW101, a synthetic T3 analogue small molecule therapy for MCT8 deficiency/AHDS. SRW101 has shown positive results in compassionate use and emergency IND settings. The company is preparing for a pivotal Phase III registration trial and has received Orphan Drug Designation in the US and EU as well as Rare Pediatric Disease designation. No approved therapies currently exist for this indication.

Therapeutic areas: Rare Diseases
Modalities: Small moleculeSynthetic T3 analogue (diiodothyropropionic acid, DIPTA)
Industry: Biotech

Partnerships

University of Miami (licensing partner; academic collaboration)

Beyond the preview

Go deeper on PriZm Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PriZm Therapeutics.

Explore the full profile